Literature DB >> 11413271

No association between multiple sclerosis and the Notch3 gene responsible for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).

S A Broadley1, S J Sawcer, S J Chataway, F Coraddu, A Coles, J Gray, R Roxburgh, D Clayton, D A Compston.   

Abstract

The clinical and radiological overlap between multiple sclerosis and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL; MIM 125310) raises the possibility of diagnostic confusion and suggests that pleiotropic effects of the Notch3 gene might include influencing susceptibility to multiple sclerosis. To investigate these possibilities three microsatellites markers closely flanking the Notch 3 gene in 745 simplex families with multiple sclerosis were genotyped and exon 3 and exon 4 of the gene were directly sequenced in a subset of the index members from these families (n=93). No evidence for association was found in any of the three markers and none of the commoner mutations causing CADASIL were found in the sequenced patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413271      PMCID: PMC1737440          DOI: 10.1136/jnnp.71.1.97

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  3 in total

1.  CADASIL mutation and Balo concentric sclerosis: a link between demyelination and ischemia?

Authors:  Tanuja Chitnis; Travis J Hollmann
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

2.  Periventricular Hyperintensities Mimicking Multiple Sclerosis.

Authors:  Sidra Saleem; Arsalan Anwar; Zainab Abbasi; Zauraiz Anjum; Zemal Tariq
Journal:  Cureus       Date:  2019-08-05

3.  Inflammatory-like presentation of CADASIL: a diagnostic challenge.

Authors:  Nicolas Collongues; Nathalie Derache; Frédéric Blanc; Pierre Labauge; Jérôme de Seze; Gilles Defer
Journal:  BMC Neurol       Date:  2012-08-21       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.